First Manhattan Co. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 404,888 shares of the medical equipment provider’s stock after selling 110,459 shares during the quarter. First Manhattan Co. owned 0.20% of Zimmer Biomet Holdings worth $47,408,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. MARSHALL WACE ASIA Ltd acquired a new stake in Zimmer Biomet Holdings in the first quarter valued at approximately $38,621,000. Ingalls & Snyder LLC boosted its stake in Zimmer Biomet Holdings by 2.6% in the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after acquiring an additional 507 shares in the last quarter. Caxton Associates LP acquired a new stake in shares of Zimmer Biomet Holdings during the first quarter worth $403,000. Koch Industries Inc. lifted its stake in shares of Zimmer Biomet Holdings by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after buying an additional 1,038,674 shares during the period. Finally, Jensen Investment Management Inc. lifted its stake in shares of Zimmer Biomet Holdings by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock worth $751,000 after buying an additional 1,140 shares during the period. 85.44% of the stock is currently owned by institutional investors and hedge funds.
Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded up $0.31 during trading hours on Tuesday, reaching $111.06. 1,275,500 shares of the company were exchanged, compared to its average volume of 1,366,155. The firm has a market cap of $22,423.90, a PE ratio of 13.72, a P/E/G ratio of 1.72 and a beta of 1.17. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same quarter in the prior year, the company earned $1.79 EPS. The firm’s revenue for the quarter was down .8% on a year-over-year basis. analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2017/11/14/zimmer-biomet-holdings-inc-zbh-stake-lessened-by-first-manhattan-co.html.
Several equities research analysts have recently commented on the stock. Morgan Stanley lifted their price objective on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 17th. BidaskClub cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Canaccord Genuity cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and cut their price objective for the company from $141.00 to $135.00 in a report on Friday, July 28th. Cantor Fitzgerald set a $137.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “hold” rating in a report on Thursday, July 27th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet Holdings currently has a consensus rating of “Hold” and a consensus target price of $133.71.
Zimmer Biomet Holdings Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.